US Stock MarketDetailed Quotes
TRVI Trevi Therapeutics
- 3.150
- +0.070+2.27%
Close Sep 26 16:00 ET
- 3.150
- 0.0000.00%
Post 16:09 ET
228.66MMarket Cap-8289P/E (TTM)
3.160High2.940Low1.82MVolume3.130Open3.080Pre Close5.63MTurnover4.18%Turnover RatioLossP/E (Static)72.59MShares4.00052wk High3.45P/B137.01MFloat Cap0.97052wk Low--Dividend TTM43.50MShs Float10.620Historical High--Div YieldTTM7.16%Amplitude0.460Historical Low3.097Avg Price1Lot Size
Trevi Therapeutics Stock Forum
Sign in to post a comment
$Trevi Therapeutics (TRVI.US)$ Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF) 2 MINUTES AGO, 7:30 AM EST VIA PR NEWSWIRE![]()
1
6
$Trevi Therapeutics (TRVI.US)$ Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio™ in Prurigo Nodularis 5 MINUTES AGO, 8:30 AM EDT VIA PR NEWSWIRE TRVI SHARE Continued reduction in WI-NRS observed among participants who remained in the study through 52 weeks of treatment Safety data over 52 weeks: treatment was well tolerated and consistent with 14-week blinded safety data Preliminary analyses presented at the European Academy of Dermatology & V...
$Trevi Therapeutics (TRVI.US)$ Long Buyers better Sell Off and enjoy your Gain 🤗👌👍, if greedy then check CS & BXRX 😏😩😪
$Trevi Therapeutics (TRVI.US)$ Gap = Range = Bid & Ask >2 cents, it is no good to Trade 👉 Must be Deleted out of your Watchlist 👹👺👊
$Trevi Therapeutics (TRVI.US)$
Test could not Short then Delete 😞
Test could not Short then Delete 😞
$Trevi Therapeutics (TRVI.US)$ $Corvus Pharmaceuticals (CRVS.US)$ $Vroom (VRM.US)$ $Exela Technologies (XELA.US)$ $Inovio Pharmaceuticals (INO.US)$ $Mereo BioPharma (MREO.US)$ $Powerbridge Technologies (PBTS.US)$
$Guardforce AI (GFAI.US)$ @simple fong @与股共存 @小仙女菩萨
@ $Meta Materials (MMAT.US)$ @ INO is climbing soon.
$Guardforce AI (GFAI.US)$ @simple fong @与股共存 @小仙女菩萨
@ $Meta Materials (MMAT.US)$ @ INO is climbing soon.
$Trevi Therapeutics (TRVI.US)$ Ayer, el ensayo de fase 2b/3 (PRISM) de Trevi Therapeutics Inc (NASDAQ:TRVI) que evaluó Haduvio (nalbufina ER) para el prurigo nodular (PN) cumplió con éxito los criterios de valoración primarios y secundarios clave.
Needham escribe que Haduvio tuvo un inicio de acción rápido, alcanzando la estadística sig a las 6 semanas con una eficacia que aún no se había estancado en la lectura de la semana 14.
Trevi se reunirá con la FDA antes de iniciar un ensayo de fase 3 que...
Needham escribe que Haduvio tuvo un inicio de acción rápido, alcanzando la estadística sig a las 6 semanas con una eficacia que aún no se había estancado en la lectura de la semana 14.
Trevi se reunirá con la FDA antes de iniciar un ensayo de fase 3 que...
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Massinooo : Is this ticker good to trade?
Trytosaveabit OP Massinooo : It will be eventually! Im still looking for bottom?![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Massinooo : I have it for 1.16 you think I should hold?
Trytosaveabit OP Massinooo : If you don’t mind averaging down some if need be? Im sorry! I just can’t say whether to buy or sell? I only say what I’m doing! I would hate to be responsible for someone losing! Grrr! Sorry but I’m rooting for you!![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Massinooo : Totally understand bro. I’ll keep an eye on it after market opens and will decide. Thank you bro
View more comments...